Comprehensive biobanking strategy with clinical impact at the European Cancer Moonshot Lund Center.

Journal: Journal of proteomics
PMID: 40246065

Abstract

This white paper presents a comprehensive biobanking framework developed at the European Cancer Moonshot Lund Center that merges rigorous sample handling, advanced automation, and multi-omic analyses to accelerate precision oncology. Tumor and blood-based workflows, supported by automated fractionation systems and standardized protocols, ensure the collection of high-quality biospecimens suitable for proteomic, genomic, and metabolic studies. A robust informatics infrastructure, integrating LIMS, barcoding, and REDCap, supports end-to-end traceability and realtime data synchronization, thereby enriching each sample with critical clinical metadata. Proteogenomic integration lies at the core of this initiative, uncovering tumor- and blood-based molecular profiles that inform cancer heterogeneity, metastasis, and therapeutic resistance. Machine learning and AI-driven models further enhance these datasets by stratifying patient populations, predicting therapeutic responses, and expediting the discovery of actionable targets and companion biomarkers. This synergy between technology, automation, and high-dimensional data analytics enables individualized treatment strategies in melanoma, lung, and other cancer types. Aligned with international programs such as the Cancer Moonshot and the ICPC, the Lund Center's approach fosters open collaboration and data sharing on a global scale. This scalable, patient-centric biobanking paradigm provides an adaptable model for institutions aiming to unify clinical, molecular, and computational resources for transformative cancer research.

Authors

  • Henriett Oskolas
    Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Sweden.
  • Fábio C N Nogueira
    Research Center for Precision Medicine, IBCCF & Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Gilberto B Domont
    Research Center for Precision Medicine, IBCCF & Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Kun-Hsing Yu
    Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Yevgeniy R Semenov
    Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Peter Sorger
    Department of Systems Biology, Harvrad Medical School, Boston, MA, USA.
  • Erik Steinfelder
    eMolecules Inc., San Diego, CA, USA.
  • Les Corps
    Alderley Park, Macclesfield, Cheshire, England, United Kingdom.
  • Lesley Schulz
    Tecan Group Ltd., Männedorf, Switzerland.
  • Elisabet Wieslander
    Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Sweden.
  • David Fenyö
    Department of Biochemistry and Molecular Pharmacology, Institute for Systems Genetics, New York University Grossman School of Medicine, New York, USA.
  • Sarolta Kárpáti
    Department of Dermatology, Venerology and Dermato oncology, Semmelweis University, Budapest, Hungary.
  • Péter Holló
    Department of Dermatology, Venerology and Dermato oncology, Semmelweis University, Budapest, Hungary.
  • Lajos V Kemény
    Department of Dermatology, Venerology and Dermato oncology, Semmelweis University, Budapest, Hungary; Department of Physiology, HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Balazs Dome
    Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary; National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Translational Medicine, Lund University, Lund, Sweden.
  • Zsolt Megyesfalvi
    Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary; National Koranyi Institute of Pulmonology, Budapest, Hungary.
  • Krzysztof Pawłowski
    Department of Molecular Biology, University of Texas Southwestern Medical Center, TX, USA.
  • Toshihide Nishimura
    Board of Directors, Japan Society of Clinical Proteogenomics, Tokyo, Japan.
  • HoJeong Kwon
    Chemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
  • Sergio Encarnación-Guevara
    Center for Genomic Sciences, National Autonomous University of Mexico, Cuernavaca, Mexico.
  • A Marcell Szasz
    Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
  • Zoltán Veréb
    University Hospital Szeged Biobank, Szeged, Hungary.
  • Rolland Gyulai
    Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  • István Balázs Németh
    Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  • Roger Appelqvist
    Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Sweden.
  • Melinda Rezeli
    Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Sweden.
  • Bo Baldetorp
    Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Peter Horvatovich
    Department of Analytical Biochemistry, Faculty of Science and Engineering, University of Groningen, Groningen, the Netherlands.
  • Johan Malmström
    Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden; BioMS, Department of Mass Spectrometry, Lund University, Lund, Sweden.
  • Indira Pla
    Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA.
  • Aniel Sanchez
    Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA.
  • Beatrice Knudsen
    Department of Pathology, University of Utah, Salt Lake City, UT, USA.
  • András Kiss
    2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
  • Johan Malm
    Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Sweden.
  • György Marko-Varga
    Board of Directors, Japan Society of Clinical Proteogenomics, Tokyo, Japan; Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary; 1st Department of Surgery, Tokyo Medical University, Tokyo, Japan.
  • Jeovanis Gil
    Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Sweden. Electronic address: jeovanis.gil_valdes@med.lu.se.

Keywords

External Resources

Popular Topics
Recent Journals